The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

Exciting developments in cancer treatment were unveiled at the AACR meeting. Boehringer Ingelheim's zongertinib shows a 71% ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market.

Merck & Co. will grow its U.S. manufacturing footprint with a $1 billion plant in Delaware, becoming the latest drugmaker to ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

Three stocks that offer yields of more than 3% and which are trading near their 52-week lows today are Merck ( MRK -0.81%), ...

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US.

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

The American Association for Cancer Research’s annual conference continued Monday with Roche offering a postmortem for its ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...